- Home
- ARHS vs KALV Comparison
ARHS vs KALV Comparison
Compare ARHS & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARHS | KALV |
|---|---|---|
| Founded | 1986 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 956.8M | 1.0B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ARHS | KALV |
|---|---|---|
| Price | $6.36 | $26.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $10.78 | ★ $32.60 |
| AVG Volume (30 Days) | 1.4M | ★ 5.4M |
| Earning Date | 05-07-2026 | 07-09-2026 |
| Dividend Yield | ★ 4.78% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $1,379,222,000.00 | $50,000,000.00 |
| Revenue This Year | $7.23 | $185.42 |
| Revenue Next Year | $7.10 | $59.23 |
| P/E Ratio | $318.50 | ★ N/A |
| Revenue Growth | 8.51 | ★ 495.66 |
| 52 Week Low | $5.57 | $9.83 |
| 52 Week High | $12.97 | $26.85 |
Technical Indicators
Market Signals| Indicator | ARHS | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 44.54 | 74.68 |
| Support Level | $6.17 | $14.25 |
| Resistance Level | $7.62 | $26.85 |
| Average True Range (ATR) | 0.35 | 0.07 |
| MACD | -0.02 | -0.22 |
| Stochastic Oscillator | 36.65 | 71.05 |
Price Performance
Historical ComparisonAbout ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.